{"product_id":"veracyte-value-chain-analysis","title":"Veracyte Value Chain Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Value Chain Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Veracyte Value Chain Analysis gives you a clear, company-specific view of how Veracyte creates value across support activities and primary activities. The page already includes a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eupport Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirm Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte’s firm infrastructure ties regulatory, quality, finance, and reimbursement teams to one diagnostics model. That setup helps move genomic tests from development into clinical use across thyroid, lung, breast, and prostate cancer, while keeping evidence and payer access aligned. In 2025, that mattered because diagnostics growth depends on fast approval, clean data, and repeatable coverage decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Resource Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte depends on scientists, lab personnel, bioinformaticians, medical affairs staff, and commercial teams, so human resource management is a core control point. Training keeps specimen handling, data interpretation, and physician communication consistent, which helps protect test quality and turnaround times. In 2025, this talent mix still matters because Veracyte’s growth model relies on scaling testing volume without letting error rates rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s technology development is its key edge: its business depends on advanced genomic tests, not broad lab volume. In FY2025, that means ongoing work on assay design, bioinformatics, and clinical validation across 3 major areas: thyroid cancer, lung cancer, and interstitial lung disease.\u003c\/p\u003e\n\u003cp\u003eBetter test performance supports sharper differentiation, faster physician adoption, and stronger pricing power. For Veracyte, each gain in sensitivity or specificity can lift clinical trust and widen the moat around its test portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte’s procurement must secure reagents, consumables, sample-collection kits, and specialized lab equipment from qualified suppliers to keep assays consistent and avoid supply shocks. In a test-based model, disciplined buying protects gross margin because every kit, reagent, and instrument affects unit economics and throughput. Tight supplier control also matters as Veracyte scales its diagnostics volume and depends on reliable lab input quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte’s scaling edge: support activities fueling 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s support activities are built to scale a single diagnostics platform: firm infrastructure, skilled people, and assay R\u0026amp;D all serve clinical adoption. In 2025, this mattered most in 3 core areas—thyroid, lung, and interstitial lung disease—where quality control, payer support, and lab execution shape volume growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupport activity\u003c\/th\u003e\n\u003cth\u003e2025 takeaway\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology development\u003c\/td\u003e\n\u003ctd\u003e3 core disease areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman resources\u003c\/td\u003e\n\u003ctd\u003eLab and bioinformatics talent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear framework for analyzing Veracyte’s value-creating activities and operational chain\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Veracyte Value Chain snapshot to quickly identify operational pain points and value drivers.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erimary Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte receives patient specimens from physicians, hospitals, and other care sites, so inbound logistics starts with tight accessioning and chain-of-custody checks. In FY2025, each sample must be tracked fast and accurately because the test workflow depends on specimen integrity.\u003c\/p\u003e\n\u003cp\u003eStrong intake controls cut delays, rework, and rejected samples, which protects turnaround time and lab efficiency. One bad tube can slow the whole diagnostic path, so Veracyte’s inbound process is a direct quality gate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte’s operations turn raw tissue and blood samples into clinically actionable genomic results through molecular testing, bioinformatics, and tight quality control. In fiscal 2025, that workflow supported decisions in hard-to-diagnose cancers and helped keep turnaround times and result consistency aligned with clinical use. Strong lab operations also matter for scale, because every added test must preserve accuracy while lowering rework and delay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Veracyte's outbound logistics, results are sent to ordering clinicians and care teams through secure digital reporting channels, so the test can quickly become a treatment decision. In 2025, that fast, accurate delivery is critical because many oncology and thyroid care paths move in days, not weeks. A clean outbound flow also lowers the risk of delays, repeat calls, and missed follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte’s marketing and sales are education-led, not commodity-led, because it sells clinical utility. The team has to explain evidence to physicians, health systems, and payers, then support reimbursement so validated tests turn into adoption and revenue.\u003c\/p\u003e\n\u003cp\u003eThis matters in 2025 as Veracyte kept scaling a diagnostics model built on clinical proof, not price alone. Selling starts with data, then moves to coverage, workflow fit, and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte service covers physician support, result-interpretation help, and reimbursement help after the test is delivered. In 2025, that post-sale support matters because clinicians often need help turning genomic results into treatment choices, coding, and payer claims. Strong service can lift trust, repeat use, and long-term customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte’s FY2025 Genomic Testing Value Chain, Made Fast and Accurate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s primary activities in FY2025 convert patient samples into actionable genomic reports, then move those results to clinicians fast. Its value chain depends on sample intake, lab testing, digital delivery, and post-test support, all of which must stay accurate to protect turnaround time and clinical trust.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrimary activity\u003c\/th\u003e\n\u003cth\u003eFY2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperations\u003c\/td\u003e\n\u003ctd\u003eGenomic testing and QC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutbound logistics\u003c\/td\u003e\n\u003ctd\u003eSecure result delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003ctd\u003eInterpretation and reimbursement help\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Veracyte Value Chain Analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full report, so what you see here is exactly what you’ll download after checkout.\u003c\/p\u003e\n\u003cp\u003ePurchase unlocks the complete, detailed Veracyte Value Chain Analysis version in full.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57353577529675,"sku":"veracyte-value-chain-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/veracyte-value-chain-analysis.webp?v=1779166533","url":"https:\/\/valuechainanalysis.com\/products\/veracyte-value-chain-analysis","provider":"Value Chain Analysis","version":"1.0","type":"link"}